November 2025 Statement on the acceptance by the FDA of Echosens’ Letter of Intent for Drug Development Tool (DDT)
September 2025 A New Era for Liver Care: Prof. Dr. Jörn Schattenberg on the EC Approval of Rezdiffra™ for MASH
November 2021 Highlights from 2021 AASLD Liver Meeting: Early Detection and Monitoring with FibroScan® Mitigates Risk of Patients Developing Fibrosis/Cirrhosis
Dezember 2025 Link Between Non-alcoholic Fatty Liver Disease, Obesity and Liver Cancer Calls for Early Detection and Monitoring
FibroScan®
